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Background:  SCD-HeFT included patients with NYHA class II or III heart failure and an ejection fraction (EF) of ≤35%. Non-sustained (≥3 
beats,<30 seconds) ventricular tachycardia ≥120 bpm (NSVT) may increase risk of sudden cardiac death (SCD). We hypothesized that NSVT on 
baseline Holter monitor (HM), would be associated with increased overall mortality.
Methods:  HM was obtained in the two weeks prior to randomization to placebo, amiodarone, or ICD. HM analysis included characterization of 
NSVT. Holter staff and readers were blinded to clinical parameters, randomization status and outcomes. Statistical analysis was done using Cox 
models containing 15 previous prognostic baseline SCD-HeFT covariates, including age, EF, and NYHA class.
Results:  From 2521 patients randomized, 2040 (81%) HM had 24±6 hours of readable data. No NSVT was seen on 1367 (67%), with ≥1 NSVT 
on 673 (33%), ≥2 NSVT on 402 (20%), and ≥3 NSVT on 291 (14%). Mode, median, mean, and maximum of NSVT episodes were 1, 2, 16 (m =126), 
and 2995. Mean rate and duration were 155 bpm and 4.5 beats. Table 1 shows overall mortality by NSVT episode frequency. NSVT predicts overall 
mortality when there are ≥2 NSVT episodes, and confers greater overall mortality in each group randomized.
Table 1: Overall Mortality by NSVT Episode Frequency
NSVT
All Patients
N/Deaths (%)
Placebo
N/Deaths (%)
Amiodarone
N/Deaths (%)
ICD
N/Deaths (%)
All Patients Deaths
0 episode 1367/317 (23%) 465/121 (26%) 474/111 (23%) 428/85 (20%)
Hazard Ratio
(CI)
p
1 episode 271/71 (26%) 86/23 (27%) 73/25 (34%) 112/23 (21%)
1.00
(0.77,1.30)
[versus 0]
0.99
≥2 episodes 402/152 (38%) 136/58 (43%) 127/49 (39%) 139/45 (32%)
1.45
(1.19,1.77)
[versus≤1]
0.0002
Conclusions:  In SCD-HeFT 673 (33%) patients had NSVT, 271 had 1 NSVT and 402 had ≥2 NSVT episodes on baseline HM. Presence of only 
1 episode of NSVT on baseline HM did not, whereas ≥2 NSVT episodes did, confer increased overall mortality compared to less frequent NSVT 
episodes.
